IFNAR1 and obesity due to melanocortin 4 receptor deficiency: Thus, it is plausible that novel pharmacological intervention into the type I IFN/IFNAR axis function, in both adipocytes and immune cells, would provide alternative approaches to dampen type I IFN-driven diseases, including obesity-associated metabolic harm.